MedTrace Logo

Needle-Free Monitoring for IVF Patient Cycles

NCT03162809 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2020-08-12

No results posted yet for this study

Summary

Salivary diagnostic testing is emerging as a less invasive, inexpensive alternative to serum analyte measurements with proven diagnostic accuracy in clinical settings. This study aims to continue analyzing aspects of the performance of salivary hormone competitive immunoassays for monitoring patient's reproductive hormone profiles in the reproductive cycle. Hormone levels will be monitored during treatment cycles for infertility.

Conditions

Sponsors & Collaborators

  • Boston IVF

    lead OTHER

Principal Investigators

  • Denny Sakkas, PhD · Boston IVF

Eligibility

Min Age
25 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-09
Primary Completion
2021-04-30
Completion
2021-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03162809 on ClinicalTrials.gov